Table 2.

Adverse effects of temozolomide and O6BG on body weight

GroupMean nadir weight loss, mean ± SE (%)Maximum weight gain, mean ± SE (%)
No modulation
    ILI + 10% DMSO (control; n = 6)−6.2 ± 3.22.7 ± 2.0
    ILI + 350 mg/kg temozolomide (n = 6)−5.4 ± 1.01.2 ± 1.9
    ILI + 750 mg/kg temozolomide (n = 6)−3.3 ± 1.33.1 ± 1.3
Modulation with 3.5 mg/kg O6BG
    ILI + 350 mg/kg temozolomide (n = 6)−1.8 ± 0.83.5 ± 1.2
    ILI + 750 mg/kg temozolomide (n = 6)−5.3 ± 1.93.9 ± 1.5
Modulation with 3.5 mg/kg O6BG × 5 d
    ILI + 10% DMSO (control; n = 6)−3.3 ± 1.43.0 ± 1.5
    ILI + 350 mg/kg temozolomide (n = 6)−6.7 ± 2.97.3 ± 3.5
    ILI + 750 mg/kg temozolomide (n = 6)−7.5 ± 1.64.4 ± 1.6
    Systemic 35 mg/kg temozolomide (n = 6)−8.8 ± 2.91.6 ± 1.8